Sanofi focuses on primary care to drive China expansion

French drugmaker Sanofi (Euronext: SAN) has signalled its intention to introduce six innovative drugs and vaccines to the Chinese market “as early as possible.”

The firm outlined its strategy for expansion at the China Health Road Symposium, highlighting Aubagio (teriflunomide), the first oral new drug for the treatment of multiple sclerosis in China. Multiple sclerosis was included on the country’s "First List of Rare Diseases" in May.

At the event, the firm also discussed the importance of integrating with primary care providers - community health centers and county hospitals - institutions that were described as "county-level health gatekeepers."